A post hoc analysis of Victoza (liraglutide) shows reductions in CV risk for patients with type 2 diabetes- Novo Nordisk

Findings from a post hoc analysis of the LEADER cardiovascular (CV) outcomes trial showed that treatment with Victoza (liraglutide), from Novo Nordisk, resulted in similar reductions in the risk of major cardiovascular events in people with type 2 diabetes at high CV risk, regardless of whether or not they experienced an episode of severe hypoglycaemia during the trial. For the overall LEADER population, regardless of treatment group, people who experienced a severe hypoglycaemic episode were at a significantly greater risk of major cardiovascular adverse events (CV death, non-fatal heart attack or non-fatal stroke), CV-death or non-CV death. The risk of a CV event was far greater within 60 days of a severe hypoglycaemic episode occurring. At the same time, people treated with Victoza experienced significantly fewer episodes of severe hypoglycaemia when compared to placebo, both in addition to standard of care.

Over a median follow-up of 3.8 years, Victoza significantly reduced the risk of the composite primary endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke by 13% vs placebo. There was a significant 22% reduction in cardiovascular death with Victoza treatment vs placebo and non-significant reductions in non-fatal myocardial infarction and non-fatal stroke. Results were presented at the American Diabetes Association 77th Scientific Sessions.